Stockreport

RARE's Phase III OTC Deficiency Study Data in Detail [Yahoo! Finance]

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF The candidate is designed to provide durable expression and activity of OTC following a single intravenous infusion. DTX301 enjoys the Orphan Drug designation in the Un [Read more]